-
Something wrong with this record ?
Sirtuin-activating compounds (STACs) alleviate D-galactosamine/lipopolysaccharide-induced hepatotoxicity in rats: involvement of sirtuin 1 and heme oxygenase 1
M. K. Kemelo, N. Kutinová Canová, A. Horinek, H. Farghali
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Galactosamine toxicity MeSH
- Heme Oxygenase (Decyclizing) antagonists & inhibitors metabolism MeSH
- Heterocyclic Compounds, 4 or More Rings pharmacology therapeutic use MeSH
- Rats MeSH
- Chemical and Drug Induced Liver Injury drug therapy metabolism MeSH
- Lipopolysaccharides toxicity MeSH
- Random Allocation MeSH
- Rats, Wistar MeSH
- Sirtuin 1 metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Sirtuin activating compounds (STACs) attenuate various type of liver insults through mechanisms which are not fully understood. In the present study, we investigated the ameliorative potential of quercetin (natural polyphenol) and SRT1720 (synthetic SIRT1 activator) against D-galactosamine/lipopolysaccharide-induced hepatotoxicity (an experimental model of acute liver failure). Moreover, we compared and contrasted the roles of stress responsive enzymes, sirtuin 1 (SIRT1) and heme oxygenase 1 (HO-1) in hepatoprotection/ hepatotoxicity. Liver injury was induced in male Wistar rats by intraperitoneal injection of D-galactosamine (400 mg/kg) and lipopolysaccharide (10 microg/kg). Some animals were pretreated with quercetin (50 mg/kg i.p.) or SRT1720 (5 mg/kg i.p.). Twenty-four hours later, the effects of these treatments were evaluated by biochemical studies and Western blot. D-GalN/LPS treatment upregulated HO-1 expression, downregulated SIRT1 expression, decreased AST: ALT ratio and markedly increased bilirubin, catalase and conjugated diene levels. Pretreatment of D-GalN/LPS rats with either quercetin or SRT1720 returned SIRT1 expression, HO-1 expression and all the aforementioned markers towards normal. Collectively, these findings suggest that elevated HO-1 and low SIRT1 expressions are involved in the pathogenesis of D-GalN/LPS-induced hepatotoxicity. Drugs that downregulate HO-1 and/or upregulate SIRT1 seem to have antihepatotoxic effects and need further exploration.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016060
- 003
- CZ-PrNML
- 005
- 20180524145611.0
- 007
- ta
- 008
- 180514s2017 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.933488 $2 doi
- 035 __
- $a (PubMed)28248534
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Kemelo, Mighty Kgalalelo. $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic $7 xx0225018
- 245 10
- $a Sirtuin-activating compounds (STACs) alleviate D-galactosamine/lipopolysaccharide-induced hepatotoxicity in rats: involvement of sirtuin 1 and heme oxygenase 1 / $c M. K. Kemelo, N. Kutinová Canová, A. Horinek, H. Farghali
- 520 9_
- $a Sirtuin activating compounds (STACs) attenuate various type of liver insults through mechanisms which are not fully understood. In the present study, we investigated the ameliorative potential of quercetin (natural polyphenol) and SRT1720 (synthetic SIRT1 activator) against D-galactosamine/lipopolysaccharide-induced hepatotoxicity (an experimental model of acute liver failure). Moreover, we compared and contrasted the roles of stress responsive enzymes, sirtuin 1 (SIRT1) and heme oxygenase 1 (HO-1) in hepatoprotection/ hepatotoxicity. Liver injury was induced in male Wistar rats by intraperitoneal injection of D-galactosamine (400 mg/kg) and lipopolysaccharide (10 microg/kg). Some animals were pretreated with quercetin (50 mg/kg i.p.) or SRT1720 (5 mg/kg i.p.). Twenty-four hours later, the effects of these treatments were evaluated by biochemical studies and Western blot. D-GalN/LPS treatment upregulated HO-1 expression, downregulated SIRT1 expression, decreased AST: ALT ratio and markedly increased bilirubin, catalase and conjugated diene levels. Pretreatment of D-GalN/LPS rats with either quercetin or SRT1720 returned SIRT1 expression, HO-1 expression and all the aforementioned markers towards normal. Collectively, these findings suggest that elevated HO-1 and low SIRT1 expressions are involved in the pathogenesis of D-GalN/LPS-induced hepatotoxicity. Drugs that downregulate HO-1 and/or upregulate SIRT1 seem to have antihepatotoxic effects and need further exploration.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lékové postižení jater $x farmakoterapie $x metabolismus $7 D056486
- 650 _2
- $a galaktosamin $x toxicita $7 D005688
- 650 _2
- $a hemová oxygenasa (decyklizující) $x antagonisté a inhibitory $x metabolismus $7 D006419
- 650 _2
- $a heterocyklické sloučeniny tetra- a více cyklické $x farmakologie $x terapeutické užití $7 D006576
- 650 _2
- $a lipopolysacharidy $x toxicita $7 D008070
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a náhodné rozdělení $7 D011897
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a sirtuin 1 $x metabolismus $7 D056564
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kutinová-Canová, Nikolína $7 xx0103768 $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Hořínek, Aleš, $d 1961- $7 xx0061416 $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic; Third Medical Department, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Farghali, Hassan, $d 1943- $7 jn20000400659 $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 66, č. 3 (2017), s. 497-505
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28248534 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 4 $z 0
- 990 __
- $a 20180514 $b ABA008
- 991 __
- $a 20180524103505 $b ABA008
- 999 __
- $a ok $b bmc $g 1303683 $s 1012900
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 66 $c 3 $d 497-505 $e 20170228 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK118 $a Pubmed-20180514